featured
HRQoL in Patients With Triple Class–Exposed Relapsed and Refractory Multiple Myeloma Treated With Idecabtagene Vicleucel or Standard Regimens
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
Lancet Haematol 2024 Mar 01;11(3)e216-e227, M Delforge, K Patel, L Eliason, D Dhanda, L Shi, S Guo, TS Marshall, B Arnulf, M Cavo, A Nooka, S Manier, N Callander, S Giralt, H Einsele, S Ailawadhi, M Popa McKiver, M Cook, P Rodríguez-OteroFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.